Literature DB >> 23908539

Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting.

Alice B Gottlieb1, April W Armstrong.   

Abstract

Psoriasis is a multisystem disease. The cutaneous and musculoskeletal manifestations (psoriatic arthritis) are well recognized. However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members addressed the need to develop uniform, validated, standardized outcome measures for psoriatic disease, measures that are useful to all stakeholders including patients, physicians, regulators, and payers.

Entities:  

Keywords:  COMORBIDITIES; NATIONAL PSORIASIS FOUNDATION; OMERACT; PSORIASIS; PSORIATIC DISEASE

Mesh:

Year:  2013        PMID: 23908539     DOI: 10.3899/jrheum.130456

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Amentoflavone protects against psoriasis-like skin lesion through suppression of NF-κB-mediated inflammation and keratinocyte proliferation.

Authors:  Jingang An; Zhengxiao Li; Yingying Dong; Jianwen Ren; Jia Huo
Journal:  Mol Cell Biochem       Date:  2016-01-02       Impact factor: 3.396

2.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.

Authors:  Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek
Journal:  Qual Life Res       Date:  2017-09-05       Impact factor: 4.147

3.  Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Authors:  Kristina Callis Duffin; Joseph F Merola; Robin Christensen; John Latella; Amit Garg; Alice B Gottlieb; April W Armstrong
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.

Authors:  Thomas Nordstrøm Kjær; Kasper Thorsen; Niels Jessen; Karin Stenderup; Steen Bønløkke Pedersen
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

5.  The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.

Authors:  Jessica A Walsh; Heather Jones; Lotus Mallbris; Kristina Callis Duffin; Gerald G Krueger; Daniel O Clegg; Annette Szumski
Journal:  Psoriasis (Auckl)       Date:  2018-10-08

6.  Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians.

Authors:  I van Ee; E Deprez; A Egeberg; M Augustin; C Conrad; V Corazza; L Donati; J Lambert; R Lăpădatu; A Meyer; C Paul; R Penzer-Hick; K Stephen; J van der Zon; A Bewley
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-12-27       Impact factor: 9.228

Review 7.  Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.

Authors:  Gabrielle H Kingsley; David L Scott
Journal:  Psoriasis (Auckl)       Date:  2015-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.